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Abstract: 
The recent appearance of COVID-19 virus has created a global crisis due to unavailability of any vaccine 
or drug that can effectively and deterministically work against it. Naturally, different possibilities 
(including herbal medicines having known therapeutic significance) have been explored by the scientists. 
The systematic scientific study (beginning with in silico study) of herbal medicines in particular and any 
drug in general is now possible as the structural components (proteins) of COVID-19 are already 
characterized. The identified protein structures showed that the main protease of COVID-19 virus is Mpro 
or 3CLpro which is a key CoV enzyme and an attractive drug target as it plays a pivotal role in mediating 
viral replication and transcription.  In the present study structure of 3CLpro is used to study drug:3CLpro 
interactions and thus to investigate whether all or any of the main chemical constituents of Tinospora 
cordifolia (e.g., berberine (C20H18NO4), -sitosterol (C29H50O), coline (C5H14NO), tetrahydropalmatine 
(C21H25NO4) and octacosanol (C28H58O)) can be used as an anti-viral drug against SARS-CoV-2. The in 
silico study performed using tools of network pharmacology and molecular docking has revealed that the 
above mentioned phytochemicals available in Tinospora cordifolia can regulate 3CLpro protein's function 
and thus control viral replication. The selection of Tinospora cordifolia was motivated by the fact that the 
main constituents of it are known to be responsible for various antiviral activities and the treatment of 
jaundice, rheumatism, diabetes, etc.  
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1. Introduction: 
          In 2020, with the outbreak of a newly detected corona virus, the whole world is witnessing a 
pandemic situation which has put human life in crisis as more than 364400 people have already died due 
to this virus in last couple of months. Coronaviruses belong to a large family of viruses which may cause 
illness in animals and human.  In human, these viruses can cause different types of respiratory infections 
such as common cold, Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory 
Syndrome (SARS) [1]. Coronavirus disease COVID-19 is the most recently declared disease by WHO 
caused by a new member “novel coronavirus” of this virus family [2]. This new virus and disease were 
unknown before its outbreak began in Wuhan, China, in late December 2019 [3,4].  On 11 February 2020, 
the international committee on taxonomy of viruses declared the new novel coronavirus as “severe acute 
respiratory syndrome coronavirus 2” (SARS-CoV-2) [5] (originally tentatively named 2019-nCoV).  
SARS-CoV-2 is part of the Coronaviridae family of virus SARS-CoV with a genome sequences of 79.5% 
sequence matching. The members of this family are named after their crown-like appearance under the 
electron microscope caused by the surface glycoproteins that decorate the virus. The critical part of SARS-
CoV-2 is its spike protein. It recognizes a human protein that coats the insides of the nose and the cells of 
our lungs and interact with them. When the two proteins bind, the spike protein changes shape, which 
causes the cell to engulf the virus. It can then replicate, infect neighboring cells and tissues, and seriously 
damage the lung and many other organs. Only a few weeks after the virus appeared, its structural 
components (proteins) were characterized, giving the first insights on how the virus works and how we 
can fight against it. By now, structural biologists have determined more than 160 structures of nine 
different viral SERS CoV 2 proteins by X-ray crystallography. The spike protein, which protrudes from 
the lipid shell of the virus, is the principal target of vaccine or drug to act on.  If the human immune system 
were primed to recognize and counteract the spike protein, the infectivity of the virus would be much 
reduced and maybe even eliminated. COVID-19 has now become a pandemic worldwide affecting mostly 
all countries globally. It is an infectious disease with a high potential for transmission to close contacts 
through the respiratory droplets (such as coughing) and by fomites that can propagate through air at a 
minimum distance of 1 meter [6, 7]. Research performed till now suggests that  maintaining a distance of 
more than 1 meter between two individuals which is termed as ‘social distancing’/’physical distancing’ 
along with proper hand-hygiene reduces the chance of being infected by COVID-19. Though there are 
many predictions about the airborne transmission of this disease, but until now no scientifically valid 
evidence is available [8]. The most common symptoms of COVID-19 are fever, dry cough, and tiredness. 
These symptoms are usually mild and begin gradually. Some infected people become asymptomatic or 
only have very mild symptoms. The main point of concern is that at present, no specific therapies for 
COVID-19 are available and research regarding the treatment of COVID-19 are in infancy. As per current 
data of May 30th, 2020, over 58,05000 cases of COVID-19 have been confirmed worldwide, over 3,64239 
of which have resulted in death. The supportive care and non-specific treatment to ameliorate the 
symptoms of the patient are the only options currently. However, extensive research leading to clinical 
trials of both western and traditional medicines are going on to develop vaccines and medicines to prevent 
and treat COVID-19 [9].  
          To combat COVID-19, some preliminary research observations have indicated that the combinations 
of some clinically applied anti-malarial drugs (e.g., chloroquine, hydroxychloroquine) and anti-HIV 
vaccines can be used to treat CoV-2 infections. Also some conventional drugs (remdesivir, nelfinavir, 
pitavastatin, perampanel, praziquantel, etc.) have been tried as the potential inhibitor against SARS-CoV-
2 and found with certain curative effect in vitro [10, 11]. None of the clinically applied drug/vaccine 
response is found to be very encouraging till now.  Also toxicity of the drugs remain an inevitable issue 
causing serious adverse effects to the patients [12]. In short, to the best of our knowledge, no specific 
therapy and medicine for the effective treatment of COVID-19 has yet been reported. This unavailability 
of cure to this disease motivated me to investigate the possibility of inhibition of CoV-2 by some 
phytoconstituents available from some Indian medicinal plants.  Medicinal herb extracts have accumulated 
thousand-of-year’s experiences in the treatment of pandemic and endemic diseases. Since providing 
complementary and alternative treatments are still urgently needed for the management of patients with 
SARS-CoV-2 infection, research works with different phytoconstituents from various traditional 
medicinal herbs is certainly worth of investigation. For the present work, we have chosen an Indian 
medicinal plant: Guduchi Pippali (Giloy) or  Tinospora cordifolia (Figure 1). It belongs to the family of 
Menispermaceae and is found in India, Myanmar, Sri Lanka, and China. The plant is commonly used in 
traditional Ayurvedic medicine and has several therapeutic properties against jaundice, rheumatism, 
urinary disorder, skin diseases, diabetes, anemia, inflammation, allergic condition, etc. [13]. The stem of 
the plant is useful in the treatment of helminthiasis, heart diseases, leprosy, rheumatoid arthritis, etc. It 
supports the immune system by increasing the body's resistance to various infections, supports standard 
white blood cell structure, function, and levels [14]. The above mentioned pharmacological activities of 
the plant originates from its chemical constituents of different classes such as alkaloids, glycosides, 
steroids, phenolics, aliphatic compounds, polysaccharides essential oils, a mixture of fatty acids, and 
polysaccharides which are present in a different part of the plant body, including root and stem. 
Phytochemistry of all these are well documented in the literature [14]. Estimation of pharmacological 
properties of small molecules when it interacts with target protein is considered as a crucial step towards 
the drug discovery. We have selected a few phytoconstituents extracted compounds from Tinospora 
cordifolia (Figure 2). These phytoconstituents were selected after applying the proper virtual screening of 
drug-likeness rules which are set of guidelines for the structural properties of potential drug compounds, 
used for fast calculation of drug-like properties of a molecule. After virtual screening, we have evaluated 
their potential inhibition properties against CoV-2 main protease in silico by the mechanism of molecular 
docking.  Due to the fact that in vivo estimation of drug molecules is time consuming and expensive, in 
silico methods have become inevitable as we need an urgent solution of the present crisis. Information of 
chemical constituent activities has allowed the research community to explore computational molecular 
docking methods for investigating the drug-protein interactions. Variety of simulation methods and 
databases have yet been used for the in-silico prediction of target drugs [15,16].  Many groups are 
presently working on different quantum mechanical simulation techniques to search varieties of interacted 
complex configurations of different organic and inorganic systems and their interactions with different 
environments [17]. We have earlier studied the environmental effects on different organic probe molecules 
in view of their applications in various biomedical field [18]. In the presented study, we have reported 
some encouraging responses we obtained  in terms of inhibition potentials from some of the tested 
phytoconstituents of current probe system: Tinospora cordifolia. We believe that the results of the present 
study will lead to some important insights into the development of alternative drugs for COVID-19. 
2. Materials and Methods:  
2.1. Potential Target Protein Structures for  SARS-CoV-2 
          Coronaviruses have positive-sense single-stranded RNA. SARS-CoV-2 belongs to the -
coronavirus genus [19]. It has a genome size of ~30 kilobases and encodes for multiple structural and non-
structural proteins. The structural proteins include: spike (S), envelope (E), membrane (M), and  
nucleocapsid (N). Structure of SARS-CoV-2 has been identified quickly, and its genomic sequence is 
already available [3,4]. Since the virus has been discovered very recently so very few available 
immunological information (immunogenic epitopes eliciting antibody or T cell responses) about the virus 
are available until now. Until now, no therapeutics or vaccines are approved against any human-infecting 
coronaviruses. SARS-CoV-2 is closely related to the known SARS-CoV structures which allows 
utilization of this known protein structures to quickly build a model for discovery drugs against this newly 
appeared virus [3]. It is reported very recently that CoV-2 enters into host cells by the spike (S) 
glycoprotein that forms homotrimers protruding from the viral surface [20].  This spike protein interacts 
strongly with the human ACE2 (angiotensin-converting enzyme 2) receptor [21]. After entering the host 
cell, SARS-CoV-2 replicates itself through some cyclic processes. First it translates its genomic RNA 
(gRNA), then proteolysis of the translated polyprotein takes place with viral 3C-like proteinase, after that  
replication of gRNA with the viral replication complex happens which consists of RNA dependent RNA 
polymerase (RdRp), helicase, 30-to-50 exonuclease, endoRNAse, and 20-O-ribose methyltransferase; and 
lastly assembly of viral components takes place. These proteins (S) which are associated with replication 
are the primary targets of post-entry treatment drugs or vaccine design to suppress viral 
replication/infection or neutralizing antibodies (Abs) upon infection [21, 22]. SARS-CoV-2 3C like 
proteinase is already predicted to bind with different FDA approved antiviral commercially available 
drugs like atazanavir, remdesivir, efavirenz, ritonavir, lopinavir and other antiviral drugs that have a 
predicted affinity of having efficacy value Kd > 100 nM potency [23]. Prediction suggests that viral 
proteinase-targeting drugs were predicted to act more favorably on the viral replication process. For 
example, a docking study of lopinavir along with other HIV proteinase inhibitors of the CoV proteinase  
suggests atazanavir and ritonavir may inhibit the CoV proteinase in line with the inhibitory potency of 
lopinavir [23]. Though some case studies are available, until now there is no real evidence about whether 
these drugs will act as predicted against COVID-19.  Traditional drug discovery usually takes years of 
research and trial. Now the whole world is dealing with an emergency situation with an urgent need of 
required drug against this virus to save the infected lives. An alternative approach to combat this problem 
and to complement the existing procedure is to use the computer-assisted structure-based drug design 
(SBDD) or the computer‐aided drug design (CADD). In the present work, we have used a particular type 
of SBDD approach. Specifically, we tried here the in silico docking model approach to search for 
medication of COVID-19 by using two most variable viral proteins (I, II) SARS-CoV-2  protease enzyme 
Mpro   or 3CLpro as the receptor (Figure 3a,b).   
          3CLpro is a key to SERS-CoV enzyme. CoV 3CLpro is responsible for the maturation of itself and 
the subsequent maturation of the replicate polyproteins. This protein has a highly conserved catalytic 
domain from the SARS virus and is responsible for controlling several major functions of the virus like 
the replication and transcription processes of the virus which makes it an ideal target for drug development 
[24]. The functional importance of 3CLpro in the viral life cycle, together with the absence of closely 
related homologues in human creates the 3CLpro as an attractive target for antiviral drug design. Recently 
3D structure of one 3C like protease protein is unveiled by X-Ray crystallography (PDBID: 6LU7) [25]. 
Protease proteins are essential to the transmission and virulence of the virus. For a higher active therapy, 
by inhibiting these the severity of the infection will definitely be reduced. In the present work, we have 
tried to check the inhibiting and binding possibilities of two of these natural substrates in order to find the 
possibilities of effective drug design. 
2.2 Protein Receptors Preparation  
          In this work we have used two CoV-2 3CLpro  main proteases as target of the potential drug 
molecules. The proteases used are: protease in complex with an inhibitor N3 (PDBID: 6LU7) [25] referred 
to as I and the other one is protease bound to potent broad-spectrum non-covalent inhibitor X77 (PDBID: 
6W63) referred to as II [26]. The 3D structures of both were downloaded from the Protein Data Bank [27] 
and are shown in (Figure 3a,b)  without added water and hydrogen.  All the available required properties 
are described in Table 1. At the beginning of the present investigation, we cleaned all the protein structures 
by removing the existing lead components, water molecules and ions. Then we computed Gasteiger 
charges with inclusion of polar hydrogens.  Merging of non-polar and rotatable bonds were subsequently 
defined using Auto Dock and MG Tools of Auto DockVina software [28].  Lastly the in build ligands 
were removed from the protein molecules using Discovery studio 2020 [29]. Structures of the proteins 
were saved in PDB format for further analysis. Active amino acid residues which will be involved in 
mediating enzyme activity for protein-ligand interaction were predicted for each target protein using 
Ramachandran plot (Figure 3b) which provides a way to visualize dihedral angles ψ against φ of amino 
acid residues in protein structure. This two-dimensional plot shows the allowed and disfavoured values of 
ψ and φ. For each target protein the plot indicates localization of the residues on the A chain. 
2.3 Ligand drug molecules Preparations 
 
          Estimation of pharmacological properties of small molecules is considered as a crucial step towards 
the drug discovery. As in vivo estimation is time consuming and expensive, in silico methods have become 
inevitable. For in silico estimation, virtual screening of Drug-likeness rules (a set of guidelines for the 
determination of structural properties of proposed drug compounds) are used for fast calculation of drug-
like properties of a molecule.  Various drug-likeness rules (e.g., Lipinski's rule, MDDR-like rule, Veber’s 
rule, Ghose filter, BBB rule, CMC-50 like rule and Quantitative Estimate of Drug-likeness (QED)) have 
been used earlier in drug designing. Out of these different methods (rules), one of the dominant method is 
Lipinski's rule of five (RO5) which is a rule of thumb to evaluate drug-likeness or to determine if a 
chemical compound possesses certain pharmacological  properties that would make it a potential (likely) 
orally active drug in humans [30].   Candidate drugs that conform to the RO5, tend to have lower attrition 
rates during clinical trials and hence have an increased chance of reaching the market. RO5 helps in 
distinguishing between drug like and non-drug like molecules by its filters which help in early preclinical 
development and thus helps to circumvent preclinical and clinical failures.  We have done the virtual 
screening with various drug-likeness rules including RO5 rule, Veber’s rule [31], polar surface area and 
number of rotatable bonds [32]. Only after these tests, the proposed drugs having required drug-likeness 
have been used for molecular docking simulation. Specifically, based on the positive responses from 
virtual screening, we selected five phytoconstituent extracted compounds from Tinospora cordifolia as 
potential reference ligand drugs: berberine (C20H18NO4), choline (C5H14NO) and tetrahydropalmatine 
(C21H25NO4) from the group of alkaloids, -sitosterol (C29H50O) from steroids,  octacosanol (C28H58O) 
from aliphatic group. Details of the structure of these molecules were downloaded from Drug Bank [33] 
in pdb format and are described in Table 2a-e  along with various chemical and physical properties of 
these molecules. For docking the ligand file is required in pbdqt format. These ligand drug molecules have 
been saved in pdbqt format by Auto Dock Tools 1.5.6 [34].  
       2.4. Molecular docking and Visualization 
          Through molecular docking energy minimization and binding energy calculations are performed to 
validate the potential drug-target interactions. Through molecular docking interaction between small 
molecules (ligand) and protein receptor (may be an enzyme) can predict the activation or inhibition of 
enzyme.  Molecular docking can demonstrate the feasibility of any biochemical reaction from its 
computational output data. It can predict an optimized orientation of ligand on its target receptor through 
different binding modes of ligand in the groove of target molecule and thus may provide a raw material 
for the rational drug designing. Molecular docking in combination with scoring function is used to evaluate 
large databases for finding more potent, selective and efficient drug candidates in silico. Molecular 
docking programs perform these tasks through a cyclical process, in which the ligand conformation is 
evaluated by specific scoring functions. This process is carried out recursively until converging to a 
solution of minimum energy [35]. Docking mechanism uses drug’s binding properties to nucleic acid of 
target protein which establishes the correlation between drug’s molecular structure and its cytotoxicity. In 
this way molecular docking can predict whether the compound/drug is interacting with the protein/DNA. 
Molecular docking algorithms execute quantitative predictions of binding energetics, providing rankings 
of docked compounds based on the binding affinity of ligand-receptor complexes. The best confirmation 
of the ligand-receptor complexes which has lower binding energy is predicted for further analysis.  After 
getting positive prediction, the experimental procedures are made available to find out the real binding 
mode of the complex which led to the development of new drug molecule. 
          Docking-based studies are attempted to explore the binding mode of the suggested protease 
inhibitors onto the 3D model of protease of CoV-2 through Receptor-ligand docking analysis and in this 
case it is performed using AutoDock Vina [28]. The macromolecule (protein) file is saved in pdbqt format 
by Auto Dock Tools [28] and ready to be used for docking. Similarly the ligand molecule has been saved 
in pdbqt format by Auto Dock Tools. In the AutoDock Vina algorithm for configuration file the following 
values of the parameters were set: (i) number of binding modes- 9; (ii) exhaustiveness of search- 8 and 
(iii) maximum energy difference- 3 kcal/mol. Ligand centered maps were generated and Gridbox center 
was set to coordinate x y, and z of residue position of the target protein respectively. Out of all the possible 
poses (optimized ligand: protein complex structure) suggested by simulation according to the binding 
modes, the pose showing maximum hydrogen bonds and minimum binding free energy change (kcal/mol), 
as represented in the View window, were chosen as the best ligand:protein complex structure formed by 
ligand-receptor interaction. For choosing the best possible ligand:protein complex structure we have taken 
the help of root means square deviation (rmsd) method. Actually, rmsd values are calculated relative to 
the best mode and use only movable heavy atoms (ligand). Two varients are used here for the simulation. 
rmsd/lb (lower bound) and rmsd/ub (upper bound) differing in how the atoms are matched in the distance 
calculations. For the distance for upper bound is considered when the ligand has no symmetry as rmsd/ub 
matches each atom in a conformation with itself in the other conformation ignoring any symmetry. We 
have used rmsd/ub as the ligand molecules have no specific symmetry. The metabolite (ligand) making 
maximum number of H-bonds, hydrophobis bonds mostly show better capability to form covalent 
interaction and highest binding affinity with target proteins. Different output poses were analysed in 
Discovery Studio visualizer 2020 version 20.1.0.19295 [29] for the formation of non-bonded hydrogen 
bonds. The best pose structure was analysed also by other supporting hydrophobic interactions, functional 
groups of ligands with the amino acids of 3CLpro.  
 
3. Results and Discussion 
           Each expected ligand drug molecule was docked to CoV 2 3CL main protease (3CLPRO). We have 
to keep in mind that docking algorithm is nondeterministic in nature. So for a fixed receptor:ligand pair 
correct conformation, the minimum of scoring function cannot be identified by docking algorithm.  Table 
1 shows the structure of ligand and amino acids found in the active site pockets of 3CLPRO proteins I and 
II. Molecular docking is used to find out interaction of tested inhibitors: berberine, -sitosterol, choline, 
tetrahydropalmatine and octacosanol with both 3CLPRO proteins I and II. Berberine (C20H18NO4)  belongs 
to the class of organic compound known as protoberberine alkaloids and derivatives  extracted from 
Hydrastis canadensis L., Berberidaceae. It is also found in many other plants. Berberine is usually found 
in the roots, rhizomes, stems, and bark. One of the main source of berberine is Tinospora cordifolia.  
Berberine is used as a natural dye with a color index of 75160.  Due to its strong yellow fluorescence, it 
is useful in histology for staining heparin in mast cells. It is relatively toxic parenterally, but has been used 
orally for various parasitic and fungal infections and as antidiarrheal [36]. -sitosterol (C29H50O) has a 
structural similarity with cholesterol. It is used to  reduce cholesterol levels in the body. It is used as a 
constituents in many drugs for reduction of swelling. Being a steroid, β-sitosterol is a precursor of anabolic 
steroid boldenone [37]. Octacosanol (C28H58O) is a straight-chain aliphatic 28-carbon primary fatty 
alcohol that is used as a nutritional supplement. It has been studied as a potential therapeutic agent for the 
treatment of Parkinson's disease [38]. 1-octacosanol is reported to possess cholesterol-lowering effects, 
antiaggregatory properties, cytoprotective use, and ergogenic properties. Tetrahydropalmatine 
(C21H25NO4) has a role as an adrenergic agent, a non-narcotic analgesic and a dopaminergic antagonist. 
Tetrahydropalmatine is under investigation in clinical trial for the Treatment of Schizophrenia [39]. 
Choline (C5H14NO) is a nutrient that supports various bodily functions, including cellular growth and 
metabolism. Choline is involved in many processes, such as cell structure and messaging, fat transport 
and metabolism, DNA synthesis and nervous system maintenance [40]. 
          Candidate drugs that conform to the RO5, tend to have lower attrition rates during clinical trials and 
hence have an increased chance of reaching the market (Table 2a). Docking simulation was used to find 
out interaction of first inhibitor berberine with 3CLpro protein I (6LU7) which revealed 9 different poses 
based on the dock score and the pose with highest negative values of binding energy indicated maximum 
binding affinity (Table 3). For pose 2 we obtained the better interacted position for ligand: protein complex  
with the binding affinity of -7.3 kcal/mol which is lower than  highly tested COVID 19 drug chloroquine 
(-6.29 kcal/mol). To verify that this the best docked site we have also computed the Dreiding energy of 
different poses which consider the Dreiding force field  to calculate the energy of a specific structure  by 
summing energy components like bond lengths, bond angles, dihedral angles [41]. We obtained the lowest 
value of energy (415.725) for the same complex structure. The interaction energy further verified by the 
dipole moment values of ligand and target (Table 4). The strong interaction for pose 2 was further verified 
by the number of hydrogen bonded interactions and hydrophobic interactions present between protein and 
ligand in the optimized protein: ligand complex structure. Weak intermolecular interactions such as 
hydrogen bonding and hydrophobic interactions are key players in stabilizing energetically-favored 
ligands, in an open conformational environment of protein structures. It is a proven fact that hydrogen 
bonding  and  hydrophobic interactions both stabilize the ligands at the target protein site, and help alter 
binding affinity and drug efficacy [42]. We observed the presence of intermolecular hydrogen bonds and 
hydrophobic interaction between protein and berberine in its pose 2 which means better interaction 
between donor and acceptor moiety. We have repeated the molecular docking simulation of berberine 
with other 3Lpro protein II also and obtained the best ligand: protein complex structure with binding affinity 
of  -7.7 kcal/mol. For best poses of berberine: protein complexs, the donor–acceptor surface and different 
possible interactions are shown in Figure (4a,b) in 3D and 2D view. 
          We have repeated same molecular docking approach for other ligand structures: -sitosterol, 
octacosanol, Tetrahydropalmatine, Choline with protein I, protein II  and have identified their best possible 
ligand:protein interaction pose position in terms of their best binding affinity value, Dreiding energy, 
dipole moment, hydrogen bond, hydrophobic bond etc. and mentioned them all in Table 4,5.  From the 
molecular docking results for every suggested drug molecule, with their best possible ligand: target 
complex structures i.e., for best pose, the donor–acceptor surface with their  possible hydrogen bonding 
and hydrophobic interactions are shown in Figure (5-6a,b) in 3D and 2D view. Our screening identified 
that out of five possible bioactive ligand structures berberine and choline show the best possible 
potentialities to bind with the main protease enzymes (3Lpro): I and II of the CoV-2. Berberine  showed 
the best docking affinity compared to the other ligands against 3Lpro main protease enzyme. Berberine 
having less binding energy as compared to other molecules with its good  binding mode of interactions. 
After berberine the binding affinity followed by -sitosterol, octacosanol, Tetrahydropalmatine, Choline.  
Simulation results revealed that all five docking complexes showed good stability in presence of different 
inhibitors. These inhibitors also fulfil the required drug parameters according to RO5, MDDR, Veber rules 
including their molar refractivities, polarizabilities, polar surface areas and logP values. All these reported 
potential drug compounds are natural and also commercially available for further in vivo/in vitro 
validations. The information generated from this present study may be utilized in future for the 
development of more phytochemical based therapeutics against COVID-19. 
  
4. Conclusion:  
          Traditional Indian medicinal system has always been considered as a great source of information 
about the implications of various herbs and herbal formulae for the treatment of various diseases. In the 
present study, we have examined the antiviral potential of Tinospora cordifolia against SARS-CoV-2 
using molecular docking approach towards discovery of novel drug-like molecules. Tinospora cordifolia 
is an Indian medicinal plant having various type of bioactive compounds including alkaloids, steroids, 
glycosides, aliphatics, etc. Spotlight of the present study is to find an essential drug for the COVID19 
disease using the antiviral activity of these compounds.  Summarizing the docking results and interpreting 
the interaction analysis plots with best binding docking pose of phytochemicals berberine, -sitosterol, 
octacosanol, Tetrahydropalmatine, Choline from the parent herb Tinospora cordifolia with that of the 
selected 3Lpro targets I, II of main protease enzymes suggest the promising potential of these molecules to 
be used as raw drug material. Molecular docking analysis has revealed that berberine having less binding 
energy as compared to other molecules with its good binding mode of interactions. Simulation results 
have also revealed that all ten docking complexes showed stability in presence of different inhibitors. All 
these reported compounds are natural and also commercially available. The study provides a basic 
foundation and suggests that the proposed phytochemicals could serve as potential inhibitors in regulating 
the 3Lpro protein's function and controlling viral replication. Our results are expected to grab the attention 
of the researchers in the field of new drug discovery against SERS-CoV-2 for which no specific drugs or 
vaccines are available. The approach adopted here is general in nature and similar approach may be used 
to investigate the potential applications of other medicinal herbs and available drugs against COVID-19.  
In addition, the study may be extend to more precise investigation of protein-drug interaction using 
different quantum mechanical simulation methods like TDDFT, HF with modern tools like ONIOM which 
will help us to identify optimized and energetically favored drug:target-protein complex structures. 
However, such a task is computationally demanding and requires more computational resources and time. 
In a future communication, we would like to extend our work in that direction, so that if a clinical trial of 
the drug molecules studied here is aimed the same can be started with more confidence. Finally, we 
conclude this paper with a word caution that before using any outcome of an in silico study, proper in-
vitro and in-vivo studies are to be performed. 
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Table 1: Configuration required of target proteins for simulation. 
Protein: 3CLpro (PDBID: 6W63) Protein: 3CLpro (PDBID: 6LU7) 
Classification: VIRAL PROTEIN/INHIBITOR, 
main protease bound to potent broad-spectrum 
non-covalent inhibitor X77 
Classification: VIRAL PROTEIN,        
main protease in complex with an inhibitor 
N3  
Organism(s): Severe acute respiratory syndrome 
coronavirus 2 
Organism(s): Severe acute respiratory 
syndrome coronavirus 2, synthetic construct 
Molecule: 3C-like proteinase,       Mutation(s): 0 Molecule: main protease      Mutation(s):     0 
Chains:A SequenceLength: 306                                       
Gene Names: rep, 1a-1b 
Chains: A SequenceLength: 306                                        
GeneNames: rep, 1a-1b 
X-RAY DIFFRACTION DATA 
Resolution: 2.10 Å 
R-Value Free: 0.221  
R-Value Work: 0.150  
R-Value Observed: 0.157  
Space Group: P 21 21 2 
X-RAY DIFFRACTION DATA 
Resolution: 2.16 Å 
R-Value Free: 0.235  
R-Value Work: 0.202  
R-Value Observed: 0.204  
Space Group: C 1 2 1 
Length ( Å ) Angle ( ˚ ) 
a = 45.05 α = 90 
b = 63.84 β = 90 
c = 106.588 γ = 90 
 
Length ( Å ) Angle ( ˚ ) 
a = 97.931 α = 90 
b = 79.477 β = 114.55 
c = 51.803 γ = 90 
 
Macromolecule Content 
Total Structure Weight: 34.29 kDa 
Atom Count: 4995 
Residue Count: 305 
Unique protein chains: 1 
Macromolecule Content 
Total Structure Weight: 34.51 kDa  
Atom Count: 2500  
Residue Count: 312  
Unique protein chains: 2 
  
    
                              Native ligand   
 
 
                                  Native ligand   
C27 H33 N5 O2  
Table 2(a-e): Molecular configuration of ligand drug molecules 
a. Ligand: berberine (C20H18NO4) 
Property Value 
Mass 336.3612 
Chemical Formula C20H18NO4 
Toxicity and Affected 
organisms 
Not available 
State  Solid 
melting point (°C) 145 °C  
water solubility 0.000354 mg/mL 
Lipopholicity (logP) -1.3 
Hydrogen Acceptor Count 4 
Hydrogen Donor Count 0 
Polar Surface Area 40.8 Å2 
Rule of Five Yes 
Bioavailability 1 
Number of Rings 5 
Refractivity 93.52 m3·mol-1 
Polarizability 36.92 Å3 
 
c. Ligand: choline (C5H14NO) 
Property Value 
Mass 104.17 
Chemical Formula C5H14NO 
Toxicity and Affected 
organisms 
Oral rat LD50: 3400 
mg/kg, Humans and 
other mammals 
State Liquid 
melting point (°C) 244-247 °C (as 
chloride salt) 
water solubility 3.61 mg/mL 
logP -3.6 
Hydrogen Acceptor Count 1 
Hydrogen Donor Count 1 
Polar Surface Area 20.23 Å2 
Rule of Five Yes 
Bioavailability 1 
Number of Rings 0 
Refractivity 42.19 m3·mol-1 
Polarizability 12.57 Å3 
b. Ligand: -sitosterol (C29H50O) 
Property Value 
Mass 414.718 
Chemical Formula C29H50O 
Toxicity and Affected 
organisms 
Not Available 
State Solid 
melting point (°C) Not Available 
water solubility 1.84e-05 mg/mL 
logP 7.27 
Hydrogen Acceptor Count 1 
Hydrogen Donor Count 1 
Polar Surface Area 20.23 Å2 
Rule of Five Partly yes 
Bioavailability 1 
Number of Rings 4 
Refractivity 129.77 m3·mol-1 
Polarizability  54.21 Å3 
 
  
Table 3. Binding mode of each ligand:protein (Berberine: 6LU7) complex using molecular docking for 
Protein  (I). 
 
Pose Binding 
affinity 
Hydrogen 
bonded 
interaction 
Drieding 
energy 
(ligand) 
Drieding 
energy 
(protein) 
Dipolemoment 
of 
ligand(debye) 
1 -7.3 0 414.419 6,044.79 1.676 
2 -7.3 2 415.725 6,045.91 1.677 
3 -7.1 0 412.076 6,042.69 1.675 
4 -7.0 0 414.361 6,044.95 1.68 
5 -7.0 0 415.549 6,045.57 1.672 
6 -6.9 0 414.623 6,044.94 1.676 
7 -6.9 0 414.409 6,044.77 1.68 
8 -6.9 0 415.07 6,046.38 1.68 
9 -6.8 0 415.635 6,046.05 1.675 
 
 
 
 
 
d. Ligand: octacosanol (C28H58O) 
Property Value 
Mass 410.7595 
Chemical Formula C28H58O 
Toxicity and Affected 
organisms 
Not Available 
State Not Available 
melting point (°C) Not Available 
water solubility (1.25e-05 mg/mL) 
logP 10.25 
Hydrogen Acceptor Count 1 
Hydrogen Donor Count 1 
Polar Surface Area 20.23 Å2 
Rule of Five Partly yes 
Bioavailability 0 
Number of Rings 0 
Refractivity 132.56 m3·mol-1 
Polarizability 60.17 Å3 
e. Ligand: tetrahydropalmatine (C21H25NO4) 
Property Value 
Mass 355.434 
Chemical Formula C21H25NO4 
Toxicity and Affected 
organisms 
Not available 
State Not available 
melting point (°C) Not available 
water solubility (0.0246 mg/mL) 
logP 3.15 
Hydrogen Acceptor Count 5 
Hydrogen Donor Count 0 
Polar Surface Area 40.16 Å2 
Rule of Five Yes 
Bioavailability 1 
Number of Rings 4 
Refractivity 101.36 m3·mol-1 
Polarizability 39.97 Å3 
Table 4: Interaction detail for different ligands with protein I (6LU7) 
 
Ligand Best 
Binding 
affinity 
(kcal/mole
) 
Hydrogen bonded interaction 
(protein donor: ligand 
acceptor, distance in Å) 
Hydrophobic interaction 
(protein donor: ligand 
acceptor, distance in Å) 
Dipole 
moment of 
ligand 
(debye) 
Drieding 
energy 
between 
protein and 
ligand 
Berberine -7.3 (A:GLU166: - :UNK0:O, 
3.03944) 
(A:THR25:HG1 - :UNK0, 
2.98163) 
(:UNK0- :CYS145, 
5.4935) 
1.67 415.725 
-sitosterol -7.1 (:UNK0:O - A:ARG188:O, 
3.12606) 
(:MET165 -:UNK0, 
4.54304) 
1.761 1280.56 
Choline -3.4 (:UNK0:O - A:TYR54:OH, 
2.8027) 
(:UNK0:C - A:MET49:O, 
3.71379) 
(:UNK0:C- A:GLN189:OE1, 
3.61393)  
(:UNK0:C - A:HIS41, 
3.8048) 
5.374 104.198 
Tetrahydro
palmatine 
-6.4  (:UNK0:C - A:MET165, 
4.73002) 
(:UNK0:C - A:LEU167, 
4.89871) 
(:UNK0:C - A:PRO168, 
5.01258) 
(:UNK0 - A:CYS145, 
5.27402) 
(:UNK0 - A:MET165, 
4.58548) 
2.688 373.677 
octacosanol -6.6 (:UNK0:O - A:LEU141:O, 
3.37559) 
(:UNK0:C - A:HIS163:NE2, 
3.62548) 
(:UNK0 - A:ALA191, 
4.8791) 
1.257 414.094 
 
Table 5: Interaction detail for different ligands with protein II (6W63) 
Ligand Best 
Bin
ding 
affi
nity 
(kca
l/m
ole) 
Hydrogen bonded interaction 
(protein donor: ligand acceptor, 
distance in Å) 
Hydrophobic interaction (protein 
donor: ligand acceptor, distance in 
Å)  
Dipole 
mome
nt 
(debye
) 
Drieding 
energy 
between 
protein and 
ligand 
Berberine -7.7 (A:THR24:HG1 - :UNK0:O, 
2.9335) 
 
A:HIS41 - :UNK0, 3.86746 
A:HIS41 - :UNK0, 3.85981 
:UNK0 - A:CYS145, 5.40468 
1.677 426.855 
-sitosterol -8.0  A:CYS44 - :UNK0, 5.02829 
A:MET49 - :UNK0, 4.7919 
A:MET165 - :UNK0, 4.24509 
:UNK0:C - A:MET165, 4.39444 
A:HIS41 - :UNK0, 4.30937 
1.473 1,284.01 
Choline -3.3  :UNK0:C - A:HIS41, 3.6805 
:UNK0:C - A:HIS41, 3.91798 
4.177 103.961 
Tetrahydrop
almatine 
-6.4 :UNK0:C - A:MET49:O, 3.53709 A:HIS41 - :UNK0, 3.70768 
A:THR24:C,O;THR25:N - :UNK0, 
5.01159 
2.669 373.597 
octacosanol -8.1 A:ASN119:HD21 - :UNK0:O, 
2.1903 
 
A:THR25:CG2 - :UNK0, 3.80725 
A:HIS41 - :UNK0, 4.09107 
A:HIS41 - :UNK0, 4.46232 
A:HIS41 - :UNK0, 5.27182 
:UNK0 - A:CYS44, 5.37368 
:UNK0 - A:MET49, 5.27559 
:UNK0 - A:MET49, 5.22475 
1.253 414.219 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Morphology of Tinospora cordifolia  
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Figure 2: Different phytoconstituent extracted compounds from Guduchi Pippali (Giloy) or  Tinospora 
cordifolia as ligand molecules.  
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Figure 3a,b: Different phytoconstituent extracted compounds from Guduchi Pippali (Giloy) or  Tinospora 
cordifolia as ligand molecules.  
 
 
 
Target proteinI: 3CLpro (PDBID: 6LU7) without 
added hydrogen and inhibitor  
Ramchandran plot for 6LU7 
 
 
a. Target protein II: 3CLpro (PDBID: 6W63) 
without added hydrogen and inhibitor 
b. Ramchandran plot for 6W63 
 
 
 
 
Figure 4a,b: Donor: acceptor surface and possible types of interactions in best pose structure obtained 
from molecular docking for berberine: 6LU7 and berberine: 6W63 
 
 
 
  
a. 3D view of ligand: protein interaction surface due to 
hydrogen bond. 
 
Top row = berberine: 6LU7 
Lower row = berberine: 6W3W 
b. b. 2D view of ligand: protein interaction 
c. Green: conventional hydrogen bond 
Light pink: -alkyl bond 
Deep pink: - bond 
d. Sky blue: -donor hydrogen bond 
e. Yellow: -Sulphur bond 
 
 
 
 
 
 
 
Figure 5. Donor: acceptor surface and possible types of interactions in best pose structures obtained from 
molecular docking for different ligands with  COVID-19 protease enzyme 3CLpro  (6LU7). 
 
 
  
3D: Choline: 6LU7 2D: Choline: 6LU7 
 
 
3D: octacosanol: 6LU7 2D: octacosanol: 6LU7 
 
 
3D: -sitosterol: 6LU7 2D: -sitosterol: 6LU7 
 
 
3D: tetrahydropalmatine: 6LU7 2D: tetrahydropalmatine: 6LU7 
a. 3D view of ligand: protein interaction surface due to 
hydrogen bond. 
 
 
f. b. 2D view of ligand: protein interaction 
g. Green: conventional hydrogen bond 
Light pink: -alkyl bond 
Deep pink: - bond 
h. Sky blue: -donor hydrogen bond 
i. Yellow: -Sulphur bond 
 
 
Figure 6. Donor: acceptor surface and possible types of interactions in best pose structures obtained from 
molecular docking for different ligands with  COVID-19 protease enzyme 3CLpro  (6W63). 
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